Blood · 2008 · 40 citations · 18 references
Life SciencesGeneticsOncologyCancer GeneticsCytogeneticsMolecular OncologyCancer CytogeneticsCancer TranscriptomicsGene Fusions In CancerMolecular CytogeneticsOncogenic Fusion GenesPediatric LeukemiasAcute LeukemiasBcr-abl1 Fusion GeneCooperation Between Bcr-ablLeukemia ClassificationLeukemia CytogeneticsLeukemia-associated Fusion GenesTranslocation-associated Leukemias
It remains unresolved how different BCR-ABL transcripts differentially drive lymphoid and myeloid proliferation in Philadelphia chromosome-positive (Ph(+)) leukemias. We compared BCR-ABL transcript type and level with kinase domain (KD) mutation status, genotype, and phenotype in 1855 Ph(+) leukemias. Compared with e1a2/p190 BCR-ABL cases, de novo e13-e14a2/p210 Ph(+) lymphoid leukemia more frequently showed CML-type background, had higher blast-normalized BCR-ABL transcript levels, and more frequent persistent BCR-ABL transcript in the absence of detectable lymphoblasts. Secondary lymphoid blast transformation of CML was exclusively due to e13/e14a2/p210 BCR-ABL but was associated, at a much higher level than p210 myeloid transformation, with acquisition of new KD mutations and/or Ph genomic amplification. In contrast, myeloid blast transformation was more frequently accompanied by new acquisition of acute myeloid leukemia-type chromosomal aberrations, particularly involving the EVI1 and RUNX1 loci. Therefore, higher kinase activity by mutation, transcriptional up-regulation or gene amplification appears required for lymphoid transformation by p210 BCR-ABL.
18
Dynamics of chronic myeloid leukaemia
Franziska Michor, Timothy P. Hughes, Yoh Iwasa et al. · Nature · 2005 · 850 citations
Medicine, Hematology, Oncology +12
Shaoguang Li, Robert Ilaria, Ryan P. Million et al. · The Journal of Experimental Medicine · 1999 · 494 citations · Full text
B. Gleibetaner · Blood · 2002 · 344 citations · Full text
Medicine, Hematology, Oncology +14